Abstract:Abstract Background: Non-steroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer development by inhibiting cyclooxygenase (COX) enzymes responsible for the production of tumor growth promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a colon tumor suppressor that degrades prostaglandins and antagonizes COX-mediated oncogenesis. Deletion of 15-PGDH in mice results in an increased susceptibility to azoxymethane (AOM)-induced colon tumor formation and resistance to the chemopreventive effects of the COX-2 selective inhibitor, celecoxib. Similar resistance to colon adenoma prevention with celecoxib has been shown in humans with low colonic 15-PGDH levels. In this study, we expanded the panel of NSAIDs tested in a mouse colon tumorigenesis model to include sulindac and aspirin to determine if these non-selective COX-1 and COX-2 inhibitors would be a better treatment for the prevention of colon adenomas in mice genetically lacking 15-PGDH. Materials and Methods: 15-PGDH wild-type and knockout mice on a FVB/NJ background were administered azoxymethane (AOM) by i.p. injection once per week for 6 weeks at 10mg/kg dose. Concurrent with the first AOM injection, all mice were fed for the length of the study with either a control (AIN-76A) diet or diet supplemented with celecoxib (1250 ppm), sulindac (167 ppm), or aspirin (300 ppm). Mice were euthanized 14 weeks after the last AOM injection, and the colons were removed and examined under a dissecting microscope to identify all tumors and inflammatory lesions. The effect of NSAID treatment on COX inhibition was determined by measuring colonic PGE2 levels. Results: We demonstrate a significant difference in tumor formation between aspirin and sulindac treated 15-PGDH knockout mice compared to celecoxib treatment. Sulindac significantly prevented colon tumor formation while aspirin had no protective effect, despite a comparable reduction in colonic mucosal PGE2 levels by both sulindac and aspirin. Additionally, we find that treatment of celecoxib or sulindac for an extended period of time results in a significant increase in colonic inflammation in both wild-type and knockout mice, with lymphoid aggregates and large proximal colon inflammatory lesions appearing, and that the incidence of inflammatory lesions correlate with NSAID efficacy. Conclusions: These findings suggest sulindac may be the most active NSAID for colon chemoprevention in populations with low 15-PGDH, but raise the caution that this agent may also give rise to inflammatory lesions in the colon. Citation Format: Stephen P. Fink, Dawn M. Dawson, Yongyou Zhang, Adam Kresak, Earl G. Lawrence, Peiying Yang, Yanwen Chen, Jill S. Barnholtz-Sloan, Joseph E. Willis, Levy Kopelovich, Sanford D. Markowitz. Sulindac reversal of 15-PGDH mediated resistance to colon tumor chemoprevention with NSAIDs. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2815. doi:10.1158/1538-7445.AM2015-2815

Sulindac-derived RXRα Modulators Inhibit Cancer Cell Growth by Binding to a Novel Site.

NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Synthesis and SAR Study of Modulators Inhibiting Trxrα-Dependent AKT Activation.

Design, Synthesis and Biological Evaluation of Tetrazole-Containing RXRα Ligands As Anticancer Agents.

Retinoid X Receptor-Α (RXRA; RXRα)

Sulindac, a Non-Steroidal Anti-Inflammatory Drug, Mediates Breast Cancer Inhibition As an Immune Modulator.

A Novel Sulindac Derivative Lacking Cyclooxygenase-Inhibitory Activities Suppresses Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Targeting Truncated RXRα for Cancer Therapy.

Overview of the Structure-Based Non-Genomic Effects of the Nuclear Receptor RXRα

Abstract 4468: A Novel Sulindac Derivative (MDC-922) Inhibits the Growth of Human Colon Cancer Cell Lines: A Redox/polyamine-Dependent Effect

Abstract 4125: SSA, a Novel Sulindac Derivative, Inhibits Breast Cancer Cell Invasion and Migration

Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.

Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.

Sulindac Suppressed Beta-Catenin Expression in Human Malignant Cell Lines

Design, Synthesis, and Biological Evaluation of Novel Sulindac Derivatives As Partial Agonists of PPARγ with Potential Anti-Diabetic Efficacy.

Sulindac‐derived Retinoid X Receptor‐α Modulator Attenuates Atherosclerotic Plaque Progression and Destabilization in ApoE−/− Mice

Sulindac Reversal Of 15-Pgdh Mediated Resistance To Colon Tumor Chemoprevention With Nsaids

Sulindac Inhibits the Proliferation and Promotes Apoptosis of Laryngeal Cancer Cells by Down-Regulating the AKT/β-catenin Pathway

The Molecular Basis for Inhibition of Sulindac and Its Metabolites Towards Human Aldose Reductase